Table 1.
Baseline patient, tumor and treatment factors.
| Treatment regimen | N | Prop | N | Prop | N | Prop | N | Prop | P-value |
|---|---|---|---|---|---|---|---|---|---|
| Complete | Near complete | Incomplete | |||||||
| 17,451 | 15,120 | 87% | 762 | 4% | 1569 | 9% | |||
| Age | <0.0001 | ||||||||
| [18–40) | 870 | 5% | 792 | 91% | 36 | 4% | 42 | 5% | |
| [40–50) | 2018 | 12% | 1851 | 92% | 70 | 3% | 97 | 5% | |
| [50–60) | 4634 | 27% | 4174 | 90% | 184 | 4% | 276 | 6% | |
| [60–70) | 5637 | 32% | 4896 | 87% | 229 | 4% | 512 | 9% | |
| [70–80) | 3459 | 20% | 2805 | 81% | 183 | 5% | 471 | 14% | |
| [80–+) | 833 | 5% | 602 | 72% | 60 | 7% | 171 | 21% | |
| Sex | 0.0002 | ||||||||
| Male | 10,382 | 59% | 9084 | 87% | 435 | 4% | 863 | 8% | |
| Female | 7069 | 41% | 6036 | 85% | 327 | 5% | 706 | 10% | |
| Race | 0.0125 | ||||||||
| White | XX | 92% | 13,960 | 87% | XX | 4% | 1434 | 9% | |
| Black | XX | 5% | 712 | 84% | XX | 6% | 92 | 11% | |
| Asian | XX | 1% | 226 | 92% | XX | 1% | 18 | 7% | |
| Other | XX | 1% | 222 | 86% | XX | 4% | 25 | 10% | |
| Hispanic Origin | 0.4428 | ||||||||
| Non-Hispanic | 16,773 | 96% | 14,532 | 87% | 727 | 4% | 1514 | 9% | |
| Hispanic | 678 | 4% | 588 | 87% | 35 | 5% | 55 | 8% | |
| Insurance Status | <0.0001 | ||||||||
| Private Insurance | 9067 | 52% | 8153 | 90% | 340 | 4% | 574 | 6% | |
| Not Insured | 598 | 3% | 527 | 88% | 27 | 5% | 44 | 7% | |
| Govt | 7786 | 45% | 6440 | 83% | 395 | 5% | 951 | 12% | |
| Facility Type | <0.0001 | ||||||||
| Academic | XX | 41% | XX | 89% | XX | 4% | XX | 8% | |
| Community | XX | 47% | XX | 85% | XX | 5% | XX | 11% | |
| Integrated | XX | 7% | XX | 86% | XX | 5% | XX | 9% | |
| Other | XX | 0% | XX | 82% | XX | 9% | XX | 9% | |
| Suppressed (age < 40) | XX | 5% | XX | 91% | XX | 4% | XX | 5% | |
| Facility Case Load | <0.0001 | ||||||||
| <1 | 1542 | 9% | 1255 | 81% | 93 | 6% | 194 | 13% | |
| [1–5) | 8079 | 46% | 6871 | 85% | 377 | 5% | 831 | 10% | |
| [5–10) | 4351 | 25% | 3870 | 89% | 154 | 4% | 327 | 8% | |
| 10+ | 3479 | 20% | 3124 | 90% | 138 | 4% | 217 | 6% | |
| Distance to Treatment Facility | 0.0301 | ||||||||
| [0–50) | 15,360 | 88% | 13,269 | 86% | 676 | 4% | 1415 | 9% | |
| [50–100) | 1339 | 8% | 1174 | 88% | 60 | 4% | 105 | 8% | |
| [100+) | 752 | 4% | 677 | 90% | 26 | 3% | 49 | 7% | |
| Charlson/Deyo comorbidity score | <0.0001 | ||||||||
| 0 | 12,950 | 74% | 11,368 | 88% | 541 | 4% | 1041 | 8% | |
| 1 | 2824 | 16% | 2369 | 84% | 125 | 4% | 330 | 12% | |
| 2+ | 1677 | 10% | 1383 | 82% | 96 | 6% | 198 | 12% | |
| Diagnosis Year | 0.0087 | ||||||||
| 2005 | 1458 | 8% | 1221 | 84% | 82 | 6% | 155 | 11% | |
| 2006 | 1706 | 10% | 1464 | 86% | 80 | 5% | 162 | 9% | |
| 2007 | 1872 | 11% | 1633 | 87% | 78 | 4% | 161 | 9% | |
| 2008 | 1948 | 11% | 1712 | 88% | 91 | 5% | 145 | 7% | |
| 2009 | 2189 | 13% | 1871 | 85% | 102 | 5% | 216 | 10% | |
| 2010 | 2500 | 14% | 2166 | 87% | 113 | 5% | 221 | 9% | |
| 2011 | 2762 | 16% | 2430 | 88% | 105 | 4% | 227 | 8% | |
| 2012 | 3016 | 17% | 2623 | 87% | 111 | 4% | 282 | 9% | |
| Zip code income level | <0.0001 | ||||||||
| [$63K+) | 6013 | 34% | 5321 | 88% | 240 | 4% | 452 | 8% | |
| [$48K–63K) | 5098 | 29% | 4410 | 87% | 203 | 4% | 485 | 10% | |
| [$38K–$48K) | 3994 | 23% | 3399 | 85% | 197 | 5% | 398 | 10% | |
| [0–$38K) | 2346 | 13% | 1990 | 85% | 122 | 5% | 234 | 10% | |
| Surgery | <0.0001 | ||||||||
| Surgery | 14,215 | 81% | 12,666 | 89% | 542 | 4% | 1007 | 7% | |
| Biopsy only | 3236 | 19% | 2454 | 76% | 220 | 7% | 562 | 17% | |
Govt: Government, Surgery: includes both subtotal and gross total resection extent, Complete: total dose of RT ≥ 58 and ≤66 Gy delivered in dose per fraction ≥1.8 Gy and ≤2.0 Gy, Near Complete: total dose of RT ≥ 50 and <58 Gy delivered in dose per fraction ≥1.8 Gy and ≤2.0 Gy, Incomplete: total dose of RT <50 Gy delivered in dose per fraction ≥1.8 Gy and ≤2.0 Gy.
XX: To ensure anonymity of patients, NCDB requires that no cell counts <10 be reported. Cell with fewer than 10 individuals or cells with counts allowing back-calculation of small counts have been redacted.